Currently, Moleculin Biotech Inc [MBRX] is trading at $0.6, down -1.81%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The MBRX shares have lost -9.97% over the last week, with a monthly amount drifted -25.71%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Maxim Group downgraded its rating to Hold on February 12, 2025.
This stock has fluctuated between a low of $0.25 and a high of $3.65 over the last 52 weeks. Moleculin Biotech Inc [NASDAQ: MBRX] shares were valued at $0.6 at the most recent close of the market.
Analyzing the MBRX fundamentals
Gross Profit Margin for this corporation currently stands at -0.22% with Operating Profit Margin at -201.91%, Pretax Profit Margin comes in at -210.71%, and Net Profit Margin reading is -210.71%. To continue investigating profitability, this company’s Return on Assets is posted at -1.23, Equity is -16.76 and Total Capital is -1.86. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.5813 points at the first support level, and at 0.5664 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.6155, and for the 2nd resistance point, it is at 0.6348.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Moleculin Biotech Inc [NASDAQ:MBRX] is 1.15. Further, the Quick Ratio stands at 1.15, while the Cash Ratio is 0.96.
Transactions by insiders
Recent insider trading involved Foster Jonathan P., Chief Financial Officer, that happened on Jun 23 ’25 when 0.27 million shares were purchased. CEO and President, KLEMP WALTER V completed a deal on Jun 23 ’25 to buy 0.68 million shares.
